Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 8/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088620 | 1.00 | PNMT (0.41) | PNMTMAPTHTTHTR1DHTR1B | |
| SCHEMBL8549512 | 0.86 | MAPT (0.38) | MAPTHTTHTR1DHTR1BDRD2 | |
| SCHEMBL28745705 | 0.82 | MAPT (0.39) | MAPTHTTHTR1DHTR1BDRD2 | |
| SCHEMBL7092030 | 0.82 | MAPT (0.39) | MAPTHTTHTR1DHTR1BDRD2 | |
| SCHEMBL7401152 | 0.82 | HTR1D (0.46) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL7408325 | 0.82 | XBP1 (0.40) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL20718641 | 0.81 | MAPT (0.41) | PNMTMAPTHTTDRD2HTR2A | |
| SCHEMBL20699974 | 0.81 | DRD1 (0.49) | MAPTHTTHTR1DHTR1BDRD2 | |
| SCHEMBL5093605 | 0.79 | MAPT (0.43) | MAPTHTTHTR1DHTR1BCAMK2A | |
| SCHEMBL5090662 | 0.79 | MAPT (0.43) | MAPTHTTHTR1DHTR1BCAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1312148-C | Isochroman compounds for treatment of CNS disorders | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1620447-A | Isochroman compounds for treatment of cns disorders | LILLY CO ELI (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-0836599-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002259-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | PNMT 76/4885MAPT 166/4885HTT 105/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | PNMT 1709/4885MAPT 2401/4885HTT 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.